Abstract
Treatment for allergic conjunctivitis has markedly expanded in recent years, providing opportunities for more focused therapy, but often leaving both physicians and patients confused over the variety of options. As monotherapy, oral antihistamines are an excellent choice when attempting to control multiple earlyphase, and some late-phase, allergic symptoms in the eyes, nose and pharynx. Unfortunately, despite their efficacy in relief of allergic symptoms, systemic antihistamines may result in unwanted adverse effects, such as drowsiness and dry mouth. Newer second-generation antihistamines (cetirizine, fexofenadine, loratadine and desloratadine) are preferred over older first-generation antihistamines in order to avoid the sedative and anticholinergic effects that are associated with first-generation agents. When the allergic symptom or complaint, such as ocular pruritus, is isolated, focused therapy with topical (ophthalmic) antihistamines is often efficacious and clearly superior to systemic antihistamines, either as monotherapy or in conjunction with an oral or intranasal agent.
Topical antihistaminic agents not only provide faster and superior relief than systemic antihistamines, but they may also possess a longer duration of action than other classes including vasoconstrictors, pure mast cell stabilisers, NSAIDs and corticosteroids. Many antihistamines have anti-inflammatory properties as well. Some of this anti-inflammatory effect seen with ‘pure’ antihistamines (levocabastine and emedastine) may be directly attributed to the blocking of the histamine receptor that has been shown to downregulate intercellular adhesion molecule-1 expression and, in turn, limit chemotaxis of inflammatory cells. Some topical multiple-action histamine H1-receptor antagonists (olopatadine, ketotifen, azelastine and epinastine) have been shown to prevent activation of neutrophils, eosinophils and macrophages, or inhibit release of leukotrienes, platelet-activating factors and other inflammatory mediators. Topical vasoconstrictor agents provide rapid relief, especially for redness; however, the relief is often short-lived, and overuse of vasoconstrictors may lead to rebound hyperaemia and irritation. Another class of topical agents, mast cell stabilisers (sodium cromoglicate [cromolyn sodium], nedocromil and lodoxamide), may be considered; however, they generally have a much slower onset of action. The efficacy of mast cell stabilisers may be attributed to anti-inflammatory properties in addition to mast cell stabilisation. In the class of topical NSAIDs, ketorolac has been promoted for ocular itching but has been found to be inferior for relief of allergic conjunctivitis when compared with olopatadine and emedastine. Lastly, topical corticosteroids may be considered for severe seasonal ocular allergy symptoms, although long-term use should be avoided because of risks of ocular adverse effects, including glaucoma and cataract formation.
Similar content being viewed by others
References
Buscaglia S, Paolieri F, Catrullo A, et al. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro. Clin Exp Allergy 1996 Oct; 26(10): 1188–96
Woodward DF, Hawley SB, Williams LS, et al. Studies on the ocular pharmacology of prostaglandin D 2. Invest Ophthalmol Vis Sci 1990 Jan; 31(1): 138–46
Katelaris CH. Ocular allergy: implications for the clinical immunologist. Ann Allergy Asthma Immunol 2003 Jun; 90 (6 Suppl. 3): 23–7
Bielory L. Allergic and immunologic disorders of the eye. Part I: immunology of the eye. J Allergy Clin Immunol 2000; 106(5): 805–16
Tsubota K, Takamura E, Hasegawa T, et al. Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis. Cornea 1991 Nov; 10(6): 525–31
Ciprandi G, Buscaglia S, Pesce G, et al. Allergic subjects express intercellular adhesion molecule: 1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993 Mar; 91(3): 783–92
Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003 Oct; 112 (4 Suppl.): S78–82
Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998 Dec; 81(6): 601–7
Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol 1981 Feb; 99(2): 302–4
Sharif NA, Su SX, Yanni JM. 36Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 1994; 10(4): 653–64
Kakiuchi M, Ohashi T, Musoh K, et al. Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn J Pharmacol 1997 Apr; 73(4): 291–8
Ellis J, Seidenberg M. Desloratadine exhibits high affinity to-ward muscarinic acetylcholine receptors in binding and functional studies [abstract]. FASEB J 2001; 15(4): A557
Gillard M, Van der Perren C, Massingham R, et al. Binding characteristics of [3H]levocetirizine to cloned human H1-histamine-receptors expressed in CHO cells. Inflamm Res 2002 Apr; 51 Suppl. 1: S77–8
Evangelista S, Boni P, Castellucci A, et al. Antihistaminic and antiallergic properties of dextro-mequitamium iodide in upper and lower guinea pig airways: comparison with azelastine. Gen Pharmacol 1998 Apr; 30(4): 513–9
Azelastine (Optivar™) product monograph. Tewksbury (MA): Muro Pharmaceuticals, Inc., 2000 Jun: 8
Fugner A, Bechtel WD, Kuhn FJ, et al. In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneimittelforschung 1988 Oct; 38(10): 1446–53
Kubo N, Shirakawa O, Kuno T, et al. Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol 1987 Mar; 43(3): 277–82
Sharif NA, Xu SX, Miller ST, et al. Characterisation of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996 Sep; 278(3): 1252–61
Ahn HS, Barnett A. Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamine. Eur J Pharmacol 1986 Aug 7; 127(1–2): 153–5
Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002 Dec 16; 113 Suppl. 9A: 38S–46S
Zyrtec®: prescribing information [online]. Available from URL: http://www.zyrtec.com [Accessed 2004 Nov 4]
Allegra®: prescribing information [online]. Available from URL: http://www.allegra.com/seasonal-allergy-site.jsp [Accessed 2004 Nov 4]
Claritin®: prescribing information. Kenilworth (NJ): Schering-Plough Corp., 2004
Clarinex®: prescribing information [online]. Available from URL: http://www.sch-plough.com/schering_plough/pc/allergy_respiratory.jsp [Accessed 2004 Nov 4]
Schoeneich M, Pecoud AR. Effect of cetirizine in a conjunctival provocation test with allergens. Clin Exp Allergy 1990 Mar; 20(2): 171–4
Tosca M, Ciprandi G, Passalacqua G, et al. Cetirizine reduces conjunctival nonspecific hyperreactivity in children with mite allergy. J Investig Allergol Clin Immunol 1998 Jan–Feb; 8(1): 23–6
Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995 Feb; 95(2): 612–21
Grumetto L, Cennamo G, Del Prete A, et al. Pharmacokinetics of cetirizine in tear fluid after a single oral dose. Clin Pharmacokinet 2002; 41(7): 525–31
Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993 Dec; 46(6): 1055–80
Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003 Oct; 112 (4 Suppl.): S78–82
Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135–41
Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single and multiple-dose fexofenadine in healthy male volunteers. Clin Pharmacol Ther 1998; 64: 612–21
Bernstein D, Schoenwetter W, Nathan R, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443–8
Casale TB, Andrade C, Qu R. Safety and efficacy of once daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999; 20: 193–8
Wahn U, Meltzer EO, Finn Jr AF, et al. Fexofenadine is efficacious and safe in children (aged 6–11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003 Apr; 111(4): 763–9
Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety, and quality of life provided by fexofenadine 120mg, loratadine 10mg, and placebo administered once daily for the treatment of seasonal allergic rhinitis: Star Study Investigating Group. Clin Exp Allergy 2000; 30: 891–9
Howarth P, Stern M, Roi L, et al. Double-blind, placebo controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33
Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999 Jul; 104(1): 100–6
Ridout F, Shamsi Z, Meadows R, et al. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180mg alone and with alcohol, with hydroxyzine hydrochloride 50mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003 May; 25(5): 1518–38
Mansfield L, Mendoza C, Flores J, et al. Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA). Ann Allergy Asthma Immunol 2003 May; 90(5): 554–9
Ridout F, Hindmarch I. The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. Ann Allergy Asthma Immunol 2003 Apr; 90(4): 404–10
Bower EA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003 Feb; 74(2): 145–52
Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002 Jan; 32(1): 133–9
Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96: 344–7
Ciprandi G, Buscaglia S, Marchesi E, et al. Protective effect of loratadine in late phase reaction induced by conjunctival provocation test. Int Arch Allergy Appl Immunol 1993; 100: 185–9
Moinuddin R, de Tineo M, Maleckar B, et al. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004 Jan; 92(1): 73–9
Frolund L. Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis. Clin Otolaryngol 1991 Dec; 16(6): 527–31
Welch D, Ousler III GW, Nally LA, et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. Adv Exp Med Biol 2002; 506 (Pt B): 1051–5
Nevius JM, Abelson MB, Welch D. The ocular drying effect of oral antihistamines (loratadine) in the normal population: an evaluation [abstract]. Invest Ophthal Vis Sci 1999; 40 Suppl.: 2898
Simons FE, Prenner BM, Finn Jr A. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis: Desloratadine Study Group. J Allergy Clin Immunol 2003 Mar; 111(3): 617–22
Meltzer EO, Prenner BM, Nayak A, et al. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest 2001; 21(1): 25–32
Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003 Jul; 25(7): 1975–87
Levostin®: prescribing information [online]. Available from URL: http://www.us.novartisophthalmics.com/hcp/products/livostin-hcp.jsp?checked=y [Accessed 2004 Nov 4]
Patanol®: prescribing information [online]. Available from URL: http://www.alconlabs.com/us/aj/products/RxTher/A23_PatanolInfo.jhtml [Accessed 2004 Nov 4]
Zaditor™: prescribing information [online]. Available from URL: http://www.novartisophthalmics.ca/e/products/zaditor.shtml [Accessed 2004 Nov 4]
Optivar®: prescribing information [online]. Available from URL: http://www.optivar.com/prescribinginfo.html [Accessed 2004 Nov 4]
Elestat™: prescribing information [online]. Available from URL: http://www.elestat.com/practitioners [Accessed 2004 Nov 4]
Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994 Jul; 94(1): 134–6
Pipkorn U, Bende M, Hedner J, et al. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy 1985 Oct; 40(7): 491–6
Ahluwalia P, Anderson DF, Wilson SJ, et al. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol 2001 Sep; 108(3): 449–54
Azevedo M, Castel-Branco MG, Oliveira JF, et al. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991; 21: 689–94
Davies BH, Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993; 48: 519–24
Richard C, Trinquand C, Bloch-Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Eur J Ophthalmol 1998 Oct–Dec; 8(4): 207–16
Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 1995 Feb; 102(2): 310–6
Swedish GP Allergy Team. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Swedish GP Allergy Team. Allergy 1994 Sep; 49(8): 611–5
Zuber P, Pecoud A. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. J Allergy Clin Immunol 1988 Oct; 82(4): 590–4
Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998 Sep; 81(3): 211–8
Butrus S, Greiner JV, Discepola M, et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000 Dec; 22(12): 1462–72
Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000; 230: 60–3
Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003 Oct; 25(10): 2539–52
Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000 May; 84(5): 504–8
Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001 Nov; 87(5): 424–9
Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002 Jul; 24(7): 1161–74
Yamada Y, Sannohe S, Saito N, et al. Effect of ketotifen on the production of reactive oxygen species from human eosinophils primed by eotaxin. Pharmacology 2003 Nov; 69(3): 138–41
Woerly G, Loiseau S, Loyens M, et al. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003 May; 58(5): 397–406
Abelson MB, Chapin MJ, Kapik BM, et al. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol 2003 May; 121(5): 626–30
Greiner JV, Michaelson C, McWhirter CL, et al. Single dose of ketotifen fumarate.025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther 2002 Jul–Aug; 19(4): 185–93
Ganz M, Koll E, Gausche J, et al. Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. Adv Ther 2003 Mar–Apr; 20(2): 79–91
Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000; 230: 52–5
Abelson MB, Chapin MJ, Kapik BM, et al. Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. Adv Ther 2002 Jul–Aug; 19(4): 161–9
Giede C, Metzenauer P, Petzold U, et al. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000; 16(3): 153–63
James IG, Campbell LM, Harrison JM, et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003; 19(4): 313–20
Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis: a double-blind, randomized, placebo-controlled study. Allergy 1998 Sep; 53(9): 857–62
Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003; 19(4): 321–9
Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003 Nov; 132(3): 231–9
Kempuraj D, Huang M, Kandere K, et al. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002 May; 88(5): 501–6
Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997 Feb; 27(2): 182–91
el-Shazly AE, Masuyama K, Samejima Y, et al. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. Immunopharmacol Immunotoxicol 1996 Nov; 18(4): 587–95
Saito H, Yamamoto N, Tomita S, et al. Effect of emedastine difumarate on CC chemokine-elicited eosinophil migration. Int Arch Allergy Immunol 2001; 125 Suppl. 1: 22–8
Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000 Dec; 130(6): 717–23
Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001 Jun; 131(6): 691–8
Secchi A, Leonardi A, Discepola M, et al. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl 2000; 230: 48–51
Orfeo V, Vardaro A, Lena P, et al. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Eur J Ophthalmol 2002 Jul–Aug; 12(4): 262–6
Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999; 228: 43–6
Abelson MB, Kaplan AP. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10mg and their combination in the human conjunctival allergen challenge model. Clin Ther 2002 Mar; 24(3): 445–56
Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004 Jan; 26(1): 35–47
Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004 Jan; 26(1): 29–34
Abelson MB, Ghosh P, Bradford R, et al. Safety and efficacy of ophthalmic epinastine in patients with allergic conjunctivitis [abstract]. 60th Anniversary Meeting of the American Academy of Allergy, Asthma and Immunology; 2003 Mar 7–12; Denver
Friedlander M, Schachar R, Breschears D, et al. Objective evaluation of allergic reactions in the eye [abstract]. 2004 meeting of the American Society of Cataract and Refractive Surgeons (ASCRS); 2004 May 1–4; San Diego
Spangler DL, Abelson MB, Ober A, et al. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003 Aug; 25(8): 2245–67
Abelson MB, Lanier RQ. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol Scand Suppl 1999; 228: 53–6
Alexander M, Patel P, Allegro S, et al. Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis. Clin Exp Ophthal 2003; 31: 206–12
Chung KF. Effects of nedocromil sodium on airway neurogenic mechanisms. J Allergy Clin Immunol 1996 Nov; 98 (5 Pt 2): S112–6
Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003 Aug; 81(4): 378–82
Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004 Mar; 111(3): 476–82
Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol 2003 Mar; 21(1): 25–30
Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002 Sep; 89(3): 298–303
Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye 2001 Feb; 15 (Pt 1): 39–41
Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998 Sep; 105(9): 1715–20
Whitcup SM, Chan CC, Kozhich AT, et al. Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis. Clin Immunol 1999 Nov; 93(2): 107–13
Acknowledgements
No external funding was used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bielory, L., Lien, K.W. & Bigelsen, S. Efficacy and Tolerability of Newer Antihistamines in the Treatment of Allergic Conjunctivitis. Drugs 65, 215–228 (2005). https://doi.org/10.2165/00003495-200565020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565020-00004